CDR-Life Inc. has closed a $76 million series A round to advance development of a new generation of cancer immunotherapies designed to treat solid tumors by targeting intracellular antigens that occur only in tumors, with the aim of increasing effectiveness while reducing off-target effects.
Biopharmas raising money in public or private financings, including: Affimed, Aquestive, Blue Water, Crinetics, Liquidia, Lixte, Lyra, Navidea and NLS.
NEC Corp. subsidiary NEC Oncoimmunity AS recently received $4.8 million from the Coalition for Epidemic Preparedness Innovations to fund the development of vaccines for SARS-CoV-2 variants and other betacoronaviruses.
Biopharma financings for the first quarter of 2022 are at a five-year low, with 65.8% less money and 53% fewer transactions than a year ago. The industry raised $13.1 billion through 249 financings, compared with $38.3 billion from 529 transactions in 2021.
NEC Corp. subsidiary NEC Oncoimmunity AS recently received $4.8 million from the Coalition for Epidemic Preparedness Innovations to fund the development of vaccines for SARS-CoV-2 variants and other betacoronaviruses.
U.S. private equity group Carlyle is extending its reach into biotech financing through the acquisition of London-based venture capital firm Abingworth, with which it is forming Launch Therapeutics, an operating company that will fund and manage late-stage clinical development of programs sourced from pharma and biotech companies. The move will enable further scaling of the clinical co-development model Abingworth first devised in 2009.
RSS
